Vergelijking
Efinopegdutide vs. Mazdutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2055640-93-0
2259884-03-0
Molecuulmassa
geen gegevens
4790 g/mol
Halfwaardetijd
115 h
132 h
Sequentie
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteWerkingsmechanisme
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
3
4
waarvan bij mensen
3
4
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
0
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Efinopegdutide and Mazdutide?
- Efinopegdutide is classified as "Metabool", while Mazdutide is classified as "Metabool". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Efinopegdutide or Mazdutide?
- The highest available evidence level is "Humane RCT" for Efinopegdutide and "Humane RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Efinopegdutide and Mazdutide in Germany and the United States?
- Duitsland: Efinopegdutide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. Verenigde Staten: Efinopegdutide — Niet goedgekeurd, Mazdutide — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.